This could represent a great opportunity. Both cleviprex and cangrelor are in the pipeline and represent relatively low-risk opportunities.
The issue in Europe, as I understand it, isn't the premium price, it's the crappy job Nicomed has done promoting the drug. Given MDCO's expertise in marketing, I'm sure they'll be able to ramp up Angiomax sales in Europe.
Market Data 
Markets 
AI
